Next Article in Journal
Genetic Markers Associated with Field PRRSV-Induced Abortion Rates
Next Article in Special Issue
In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4
Previous Article in Journal
Human Antimicrobial Peptides as Therapeutics for Viral Infections
Previous Article in Special Issue
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
Open AccessReview

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41

by 1,†, 1,†, 1, 1,* and 1,2,*
1
Shanghai Public Health Clinical Center and School of Basic Medical Sciences, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Fudan University, Shanghai 200032, China
2
Lindsley, F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Viruses 2019, 11(8), 705; https://doi.org/10.3390/v11080705
Received: 9 July 2019 / Revised: 26 July 2019 / Accepted: 30 July 2019 / Published: 1 August 2019
(This article belongs to the Special Issue Viral Entry Pathways)
Application of highly active antiretroviral drugs (ARDs) effectively reduces morbidity and mortality in HIV-infected individuals. However, the emergence of multiple drug-resistant strains has led to the increased failure of ARDs, thus calling for the development of anti-HIV drugs with targets or mechanisms of action different from those of the current ARDs. The first peptide-based HIV entry inhibitor, enfuvirtide, was approved by the U.S. FDA in 2003 for treatment of HIV/AIDS patients who have failed to respond to the current ARDs, which has stimulated the development of several series of protein- and peptide-based HIV entry inhibitors in preclinical and clinical studies. In this review, we highlighted the properties and mechanisms of action for those promising protein- and peptide-based HIV entry inhibitors targeting the HIV-1 gp120 or gp41 and discussed their advantages and disadvantages, compared with the current ARDs. View Full-Text
Keywords: HIV-1; gp120; gp41; entry inhibitor; peptide; antibody; recombinant protein; antiretroviral drugs HIV-1; gp120; gp41; entry inhibitor; peptide; antibody; recombinant protein; antiretroviral drugs
Show Figures

Figure 1

MDPI and ACS Style

Pu, J.; Wang, Q.; Xu, W.; Lu, L.; Jiang, S. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Viruses 2019, 11, 705.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop